|Systematic (IUPAC) name|
|(what is this?)|
Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM). It has no significant affinity for the σ2 receptor. Alazocine also acts as a κ-opioid receptor agonist (Ki = 0.4 nM), and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).
- Iwamoto ET (February 1981). "Pharmacologic effects of N-allylnormetazocine (SKF-10047)". NIDA Research Monograph 34: 82–8. PMID 6783955.
- Shearman GT, Herz A (August 1982). "Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat". European Journal of Pharmacology 82 (3–4): 167–72. doi:10.1016/0014-2999(82)90506-4. PMID 6290235.
- Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research 821 (2): 516–9. doi:10.1016/S0006-8993(99)01125-7. PMID 10064839.
- Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology 6 (1): 3. doi:10.1186/1471-2210-6-3. PMC 1403760. PMID 16433932.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|